Pharma Education Center PEC

pharmaeducationcenter.it

è una Società che ha come missione l'organizzazione di Corsi in house e pubblici di elevato livello culturale nel settore Life Sciences. Nell’organizzazione di PEC, un ruolo chiave per la realizzazione della missione è affidato ai Working Groups; essi costituiscono una comunità scientifica in divenire, che offre agli iscritti opportunità di nuovi contatti, aggiornamento, scambio e condivisione di informazioni e conoscenze tecnico/scientifiche.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

INVOX PHARMA EXTENDS TENDER OFFER TO ACQUIRE F-STAR THERAPEUTICS, INC.

invoX Pharma Limited | August 05, 2022

news image

invoX Pharma Limited a wholly owned subsidiary of Sino Biopharmaceutical Limited focused on research and development and business development activities outside of China, and F-star Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that invoX has extended the expiration of its previously announced tender offer for all of the issued and outstanding shares of F-s...

Read More

Business Insights, PHARMA TECH

ENDO ANNOUNCES AGREEMENT WITH SLAYBACK PHARMA TO DISTRIBUTE PREVDUO™ THE FIRST AND ONLY FDA-APPROVED NEOSTIGMINE-GLYCOPYRROLATE COMBINATION

prnewswire | April 28, 2023

news image

Endo International plc announced that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. have executed an agreement with Slayback Pharma LLC to distribute Slayback's Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S. The U.S. Food and Drug Administration (FDA) approved Prevduo™ in February 2023 for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after sur...

Read More

Pharmacy Market

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

news image

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

Read More

NURO’S SELF-DRIVING VEHICLES TO DELIVER PRESCRIPTIONS FOR CVS PHARMACY

Techcrunch | May 28, 2020

news image

Nuro, the autonomous robotics startup that has raised more than $1 billion from SoftBank Vision Fund, Greylock and other investors, said Thursday it will test prescription delivery in Houston through a partnership with CVS Pharmacy. The pilot, which will use a fleet of the startup’s autonomous Toyota Prius vehicles and transition to using its custom-built R2 delivery bots, is slated to begin in June. The partnership marks Nuro’s expansion beyond groceries and into healthcare. L...

Read More
news image

Business Insights

INVOX PHARMA EXTENDS TENDER OFFER TO ACQUIRE F-STAR THERAPEUTICS, INC.

invoX Pharma Limited | August 05, 2022

invoX Pharma Limited a wholly owned subsidiary of Sino Biopharmaceutical Limited focused on research and development and business development activities outside of China, and F-star Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that invoX has extended the expiration of its previously announced tender offer for all of the issued and outstanding shares of F-s...

Read More
news image

Business Insights, PHARMA TECH

ENDO ANNOUNCES AGREEMENT WITH SLAYBACK PHARMA TO DISTRIBUTE PREVDUO™ THE FIRST AND ONLY FDA-APPROVED NEOSTIGMINE-GLYCOPYRROLATE COMBINATION

prnewswire | April 28, 2023

Endo International plc announced that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. have executed an agreement with Slayback Pharma LLC to distribute Slayback's Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S. The U.S. Food and Drug Administration (FDA) approved Prevduo™ in February 2023 for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after sur...

Read More
news image

Pharmacy Market

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

Read More
news image

NURO’S SELF-DRIVING VEHICLES TO DELIVER PRESCRIPTIONS FOR CVS PHARMACY

Techcrunch | May 28, 2020

Nuro, the autonomous robotics startup that has raised more than $1 billion from SoftBank Vision Fund, Greylock and other investors, said Thursday it will test prescription delivery in Houston through a partnership with CVS Pharmacy. The pilot, which will use a fleet of the startup’s autonomous Toyota Prius vehicles and transition to using its custom-built R2 delivery bots, is slated to begin in June. The partnership marks Nuro’s expansion beyond groceries and into healthcare. L...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us